Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | GI-101 |
Trade Name | |
Synonyms | GI 101|GI101 |
Drug Descriptions |
GI-101 is a bispecific protein comprising the extracellular domain of CD80, which binds to and inhibits CTLA4, and an IL-2 variant that binds to IL2RB, which potentially leads to increased antitumor immune response and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 6529). |
DrugClasses | CTLA4 Inhibitor 4 |
CAS Registry Number | NA |
NCIT ID | C181773 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
GI-101 | GI-101 | 0 | 1 |
GI-101 + Lenvatinib | GI-101 Lenvatinib | 0 | 1 |
GI-101 + Pembrolizumab | GI-101 Pembrolizumab | 0 | 1 |